Dual PDE34 and PDE4 Inhibitors

Total Page:16

File Type:pdf, Size:1020Kb

Dual PDE34 and PDE4 Inhibitors Basic & Clinical Pharmacology & Toxicology Doi: 10.1111/bcpt.12209 MiniReview Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases Katharine H. Abbott-Banner1 and Clive P. Page2 1Verona Pharma plc, London, UK and 2Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (Received 2 December 2013; Accepted 30 January 2014) Abstract: Selective phosphodiesterase (PDE) 4 and dual PDE3/4 inhibitors have attracted considerable interest as potential thera- peutic agents for the treatment of respiratory diseases, largely by virtue of their anti-inflammatory (PDE4) and bifunctional bron- chodilator/anti-inflammatory (PDE3/4) effects. Many of these agents have, however, failed in early development for various reasons, including dose-limiting side effects when administered orally and lack of sufficient activity when inhaled. Indeed, only one selective PDE4 inhibitor, the orally active roflumilast-n-oxide, has to date received marketing authorization. The majority of the compounds that have failed were, however, orally administered and non-selective for either PDE3 (A,B) or PDE4 (A,B,C,D) subtypes. Developing an inhaled dual PDE3/4 inhibitor that is rapidly cleared from the systemic circulation, potentially with sub- type specificity, may represent one strategy to improve the therapeutic index and also exhibit enhanced efficacy versus inhibition of either PDE3 or PDE4 alone, given the potential positive interactions with regard to anti-inflammatory and bronchodilator effects that have been observed pre-clinically with dual inhibition of PDE3 and PDE4 compared with inhibition of either isozyme alone. This MiniReview will summarize recent clinical data obtained with PDE inhibitors and the potential for these drugs to treat COPD and other inflammatory airways diseases such as asthma and cystic fibrosis. Chronic obstructive pulmonary disease (COPD) is a major health and faster disease progression, including decline in lung cause of morbidity and mortality and is increasing in preva- function and a higher risk of death [5]. There is also an lence. The WHO estimates that by 2020, COPD will be the increasing concern that the regular use of corticosteroids to third leading cause of death and the fifth leading cause of dis- treat patients with COPD makes such patients more suscepti- ability worldwide [1]. The disease is characterized by progres- ble to infections such as pneumonia [6]. sive airflow obstruction resulting from mucosal inflammation Chronic obstructive pulmonary disease is considered to be and oedema, bronchoconstriction, mucus hypersecretion and among the costliest inpatient conditions, with costs in the UK loss of elastic recoil. estimated to be £800 million, over half of which relates to Short-acting b2 agonists and muscarinic receptor antagonists hospital-based care. COPD is also estimated to be responsible are the first line of treatment, and as the disease progresses, for 24 million lost working days/year. Thus, there is a high long-acting b2 agonists (LABAs) and muscarinic antagonists unmet medical need that requires novel effective therapies [2]. (LAMAs), with the combination of a LABA and a LAMA, Inflammation is a characteristic feature of COPD that contrib- often becoming necessary as a maintenance therapy. In addi- utes to the airway obstruction and lung tissue destruction. tion, LABAs are typically used in combination with inhaled Whilst CD68+ macrophages and CD8+ T-lymphocytes are the corticosteroids (ICS) [2]. Despite the beneficial effects of these predominant cells in the bronchial mucosa of patients with therapies and their various combinations, modest beneficial COPD, the presence of other inflammatory cells such as effects on health-related quality of life and FEV1 have been B-lymphocytes, neutrophils and dendritic cells, together with observed [3], and corticosteroids are relatively ineffective at increased levels of pro-inflammatory mediators (e.g. IL-6, suppressing the airway wall thickening and luminal occlusion IL-1b, TNF-a, Gro-a, MCP-1, IL-8 and IL-32) in the lung in patients with COPD [4] and the consequent disease progres- [7–9], and increased levels of IL-1b, IL-6 and TNF-a in the sion. Indeed, most patients with COPD remain symptomatic blood, has also been observed. This inflammatory response and experience exacerbations of their disease, characterized by persists even in the absence of overt infection [10]. increased airway obstruction and worsening lung function, Exacerbations of COPD reflect a worsening of the underly- associated with enhanced airways inflammation. Patients with ing chronic inflammation in the airways and are characterized severe COPD and frequent exacerbations experience poorer by marked elevations in neutrophils and their products (e.g. neutrophil elastase) in the airways [11,12], together with Author for correspondence: Katharine Helen Abbott-Banner, Verona a Pharma plc, Suite 21, Alpha House, 100 Borough High Street, a significant increase in cytokines such as IL-8 and TNF- London, SE1 1LB, UK (e-mail [email protected]). which are known to act as chemoattractants for neutrophils © 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society) 2 KATHARINE H. ABBOTT-BANNER AND CLIVE P. PAGE MiniReview [11]. Interestingly, there is a significant correlation between cells (e.g. neutrophils, eosinophils) [43–46], there is little the percentage of neutrophils in bronchoalveolar lavage (BAL) evidence for selective PDE3 inhibitors inhibiting inflammatory fluid and severity of airways obstruction assessed by FEV1/ cell function. However, there is growing evidence to suggest FVC ratio [11]. Increases in eosinophils have also been that dual inhibition of PDE3 and PDE4 can be additive or reported in patients undergoing exacerbations [13]. even synergistic at suppressing inflammatory mediator release Mucus hypersecretion and reduced mucociliary clearance from other cell types which also express PDE3 that are are also distinctive features of COPD that are thought to con- thought to play a role in COPD (e.g. macrophages, dendritic tribute to airway obstruction and the progressive decline in cells, epithelial cells, lymphocytes, airway smooth muscle cells FEV1. Very importantly, ICS do not appear to have any effect and endothelial cells) [27,39,47–50]. on the accelerated decline in FEV1 [14], suggesting the need PDE3 inhibitors cause bronchodilation in man [51], and there for novel classes of anti-inflammatory drugs to reduce the pro- is evidence from pre-clinical studies to suggest that combined gression of this debilitating disease. It is interesting to note inhibition of PDE3 and PDE4 suppresses spasmogen-induced that cystic fibrosis transmembrane conductance regulator contraction of human and bovine airway smooth muscle, in a (CFTR), a chloride ion channel which plays an integral role in synergistic fashion [52,53]. PDE3 and PDE4 inhibitors have controlling the electrolyte/fluid balance and regulating muco- also been shown to activate CFTR-mediated ClÀ secretion, sug- ciliary clearance [15], is reduced in COPD patients, with gesting they may be able to stimulate mucociliary clearance expression inversely correlating with disease severity [16]. [15]. This diverse spectrum of biological effects has thus impli- Cyclic adenosine monophosphate (cAMP) and cyclic guano- cated PDE4 and PDE3/4 inhibitors as potential therapeutic sine monophosphate (cGMP) regulate a variety of cellular pro- agents for a range of disease indications involving inflamma- cesses including airway smooth muscle relaxation and tion and altered mucus production such as COPD, asthma and inflammatory mediator release [17]. The phosphodiesterase cystic fibrosis. Indeed, both the FDA and EMEA approved (PDE) enzyme family hydrolyses, cAMP and cGMP, to inac- roflumilast-n-oxide, an orally administered selective PDE4 tive 50AMP and 50GMP, respectively, and thus, inhibition of inhibitor in 2010 for the maintenance treatment of severe PDEs represents a potential mechanism by which cell func- COPD associated with bronchitis and a history of frequent tions such as airway smooth muscle relaxation and inflamma- exacerbations, as an add-on to standard treatment. Orally tory mediator release can be modulated [18]. 11 PDE gene administered PDE4 inhibitors, do, however, have a low thera- families have been identified, denoted PDE1-11, which differ peutic ratio, with particular concerns for the gastrointestinal in primary structures, affinities for cAMP and cGMP, side effects which to date have stopped their development or responses to specific effectors, sensitivities to specific inhibi- limited their wider use. It is conceivable therefore that adminis- tors and mechanisms of regulation [19]. Each family contains tration of PDE inhibitors, particularly a dual PDE3/4 inhibitor at least one member, and in some cases, the members are by the inhaled route, may offer increased efficacy with a products of more than one gene. reduced side effect potential versus an orally administered PDE4 is a low km (~1–10 lM) cAMP-specific PDE that PDE4 inhibitor. only has a weak affinity for cGMP (km > 50 lM). The PDE4 family is comprised of four genes (PDE4A, B, C, D), with Pre-clinical Data with PDE3 and PDE4 Inhibitors each gene having multiple splice variants. PDE4 gene prod- ucts have a broad tissue distribution; including the brain, gas- Bronchodilation. trointestinal tract, spleen, lung, heart, testis and
Recommended publications
  • PDE4-Inhibitors: a Novel, Targeted Therapy for Obstructive Airways Disease Zuzana Diamant, Domenico Spina
    PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease Zuzana Diamant, Domenico Spina To cite this version: Zuzana Diamant, Domenico Spina. PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease. Pulmonary Pharmacology & Therapeutics, 2011, 24 (4), pp.353. 10.1016/j.pupt.2010.12.011. hal-00753954 HAL Id: hal-00753954 https://hal.archives-ouvertes.fr/hal-00753954 Submitted on 20 Nov 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease Authors: Zuzana Diamant, Domenico Spina PII: S1094-5539(11)00006-X DOI: 10.1016/j.pupt.2010.12.011 Reference: YPUPT 1071 To appear in: Pulmonary Pharmacology & Therapeutics Received Date: 2 October 2010 Revised Date: 5 December 2010 Accepted Date: 24 December 2010 Please cite this article as: Diamant Z, Spina D. PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease, Pulmonary Pharmacology & Therapeutics (2011), doi: 10.1016/j.pupt.2010.12.011 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript.
    [Show full text]
  • The Single Cyclic Nucleotide-Specific Phosphodiesterase of the Intestinal Parasite Giardia Lamblia Represents a Potential Drug Target
    RESEARCH ARTICLE The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target Stefan Kunz1,2*, Vreni Balmer1, Geert Jan Sterk2, Michael P. Pollastri3, Rob Leurs2, Norbert MuÈ ller1, Andrew Hemphill1, Cornelia Spycher1¤ a1111111111 1 Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland, 2 Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute of Molecules, Medicines and Systems (AIMMS), Vrije a1111111111 Universiteit Amsterdam, Amsterdam, The Netherlands, 3 Department of Chemistry and Chemical Biology, a1111111111 Northeastern University, Boston, Massachusetts, United States of America a1111111111 a1111111111 ¤ Current address: Euresearch, Head Office Bern, Bern, Switzerland * [email protected] Abstract OPEN ACCESS Citation: Kunz S, Balmer V, Sterk GJ, Pollastri MP, Leurs R, MuÈller N, et al. (2017) The single cyclic Background nucleotide-specific phosphodiesterase of the Giardiasis is an intestinal infection correlated with poverty and poor drinking water quality, intestinal parasite Giardia lamblia represents a potential drug target. PLoS Negl Trop Dis 11(9): and treatment options are limited. According to the Center for Disease Control and Preven- e0005891. https://doi.org/10.1371/journal. tion, Giardia infections afflict nearly 33% of people in developing countries, and 2% of the pntd.0005891 adult population in the developed world. This study describes the single cyclic nucleotide- Editor: Aaron R. Jex, University of Melbourne, specific phosphodiesterase (PDE) of G. lamblia and assesses PDE inhibitors as a new gen- AUSTRALIA eration of anti-giardial drugs. Received: December 5, 2016 Accepted: August 21, 2017 Methods Published: September 15, 2017 An extensive search of the Giardia genome database identified a single gene coding for a class I PDE, GlPDE.
    [Show full text]
  • Signal Transduction Guide
    Signal Transduction Product Guide | 2007 NEW! Selective T-type Ca2+ channel blockers, NNC 55-0396 and Mibefradil ZM 447439 – Novel Aurora Kinase Inhibitor NEW! Antibodies for Cancer Research EGFR-Kinase Selective Inhibitors – BIBX 1382 and BIBU 1361 DRIVING RESEARCH FURTHER Calcium Signaling Agents ...................................2 G Protein Reagents ...........................................12 Cell Cycle and Apoptosis Reagents .....................3 Ion Channel Modulators ...................................13 Cyclic Nucleotide Related Tools ...........................7 Lipid Signaling Agents ......................................17 Cytokine Signaling Agents ..................................9 Nitric Oxide Tools .............................................19 Enzyme Inhibitors/Substrates/Activators ..............9 Protein Kinase Reagents....................................22 Glycobiology Agents .........................................12 Protein Phosphatase Reagents ..........................33 Neurochemicals | Signal Transduction Agents | Peptides | Biochemicals Signal Transduction Product Guide Calcium Signaling Agents ......................................................................................................................2 Calcium Binding Protein Modulators ...................................................................................................2 Calcium ATPase Modulators .................................................................................................................2 Calcium Sensitive Protease
    [Show full text]
  • Analyses of PDE-Regulated Phosphoproteomes Reveal Unique and Specific Camp-Signaling Modules in T Cells
    Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells Michael-Claude G. Beltejara, Ho-Tak Laua, Martin G. Golkowskia, Shao-En Onga, and Joseph A. Beavoa,1 aDepartment of Pharmacology, University of Washington, Seattle, WA 98195 Contributed by Joseph A. Beavo, May 28, 2017 (sent for review March 10, 2017; reviewed by Paul M. Epstein, Donald H. Maurice, and Kjetil Tasken) Specific functions for different cyclic nucleotide phosphodiester- to bias T-helper polarization toward Th2, Treg, or Th17 pheno- ases (PDEs) have not yet been identified in most cell types. types (13, 14). In a few cases increased cAMP may even potentiate Conventional approaches to study PDE function typically rely on the T-cell activation signal (15), particularly at early stages of measurements of global cAMP, general increases in cAMP- activation. Recent MS-based proteomic studies have been useful dependent protein kinase (PKA), or the activity of exchange in characterizing changes in the phosphoproteome of T cells under protein activated by cAMP (EPAC). Although newer approaches various stimuli such as T-cell receptor stimulation (16), prosta- using subcellularly targeted FRET reporter sensors have helped glandin signaling (17), and oxidative stress (18), so much of the define more compartmentalized regulation of cAMP, PKA, and total Jurkat phosphoproteome is known. Until now, however, no EPAC, they have limited ability to link this regulation to down- information on the regulation of phosphopeptides by PDEs has stream effector molecules and biological functions. To address this been available in these cells. problem, we have begun to use an unbiased mass spectrometry- Inhibitors of cAMP PDEs are useful tools to study PKA/EPAC- based approach coupled with treatment using PDE isozyme- mediated signaling, and selective inhibitors for each of the 11 PDE – selective inhibitors to characterize the phosphoproteomes of the families have been developed (19 21).
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells
    Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. K Matousovic, … , E N Chini, T P Dousa J Clin Invest. 1995;96(1):401-410. https://doi.org/10.1172/JCI118049. Research Article We studied interactions between the mitogen-activated protein kinase (MAPK) signalling pathway and cAMP-protein kinase (PKA) signaling pathway in regulation of mitogenesis of mesangial cells (MC) determined by [3H]thymidine incorporation, with or without added EGF. Forskolin or dibutyryl cAMP strongly (by 60-70%) inhibited [3H]thymidine incorporation into MC. Cilostamide, lixazinone or cilostazol selective inhibitors of cAMP-phosphodiesterase (PDE) isozyme PDE-III, inhibited mitogenesis to similar extent as forskolin and DBcAMP and activated in situ PKA, but without detectable increase in cAMP levels. Cilostamide and cilostazol were more than three times more effective at inhibiting mesangial mitogenesis than rolipram and denbufylline, inhibitors of isozyme PDE-IV, even though PDE-IV was two times more abundant in MC than was PDE-III. On the other hand, when incubated with forskolin, rolipram-enhanced cAMP accumulation was far greater (10-100x) than with cilostamide. EGF increased MAPK activity (+300%); PDE isozyme inhibitors which suppressed mitogenesis also inhibited MAPK. PDE isozyme inhibitors also suppressed PDGF-stimulated MC proliferation. We conclude that cAMP inhibits the mitogen-dependent MAPK-signaling pathway probably by decreasing the activity of Raf-1 due to PKA-catalyzed phosphorylation. Further, we surmise that minor increase in the cAMP pool metabolized by PDE-III is intimately related to regulation of mesangial proliferation. Thus, PDE isozyme inhibitors have the potential to suppress MC proliferation by a focused effect upon signaling pathways.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Phosphodiesterase Inhibitors: Their Role and Implications
    International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.1, No.4, pp 1148-1160, Oct-Dec 2009 PHOSPHODIESTERASE INHIBITORS: THEIR ROLE AND IMPLICATIONS Rumi Ghosh*1, Onkar Sawant 1, Priya Ganpathy1, Shweta Pitre1 and V.J.Kadam1 1Dept. of Pharmacology ,Bharati Vidyapeeth’s College of Pharmacy, University of Mumbai, Sector 8, CBD Belapur, Navi Mumbai -400614, India. *Corres.author: rumi 1968@ hotmail.com ABSTRACT: Phosphodiesterase (PDE) isoenzymes catalyze the inactivation of intracellular mediators of signal transduction such as cAMP and cGMP and thus have pivotal roles in cellular functions. PDE inhibitors such as theophylline have been employed as anti-asthmatics since decades and numerous novel selective PDE inhibitors are currently being investigated for the treatment of diseases such as Alzheimer’s disease, erectile dysfunction and many others. This review attempts to elucidate the pharmacology, applications and recent developments in research on PDE inhibitors as pharmacological agents. Keywords: Phosphodiesterases, Phosphodiesterase inhibitors. INTRODUCTION Alzheimer’s disease, COPD and other aliments. By cAMP and cGMP are intracellular second messengers inhibiting specifically the up-regulated PDE isozyme(s) involved in the transduction of various physiologic with newly synthesized potent and isoezyme selective stimuli and regulation of multiple physiological PDE inhibitors, it may possible to restore normal processes, including vascular resistance, cardiac output, intracellular signaling selectively, providing therapy with visceral motility, immune response (1), inflammation (2), reduced adverse effects (9). neuroplasticity, vision (3), and reproduction (4). Intracellular levels of these cyclic nucleotide second AN OVERVIEW OF THE PHOSPHODIESTERASE messengers are regulated predominantly by the complex SUPER FAMILY superfamily of cyclic nucleotide phosphodiesterase The PDE super family is large, complex and represents (PDE) enzymes.
    [Show full text]
  • Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
    International Journal of Molecular Sciences Review Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19? Mauro Giorgi 1,*, Silvia Cardarelli 2, Federica Ragusa 3, Michele Saliola 1, Stefano Biagioni 1, Giancarlo Poiana 1 , Fabio Naro 2 and Mara Massimi 3,* 1 Department of Biology and Biotechnology “Charles Darwin”, Sapienza University of Rome, 00185 Rome, Italy; [email protected] (M.S.); [email protected] (S.B.); [email protected] (G.P.) 2 Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University, 00185 Rome, Italy; [email protected] (S.C.); [email protected] (F.N.) 3 Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy; [email protected] * Correspondence: [email protected] (M.G.); [email protected] (M.M.) Received: 10 July 2020; Accepted: 24 July 2020; Published: 27 July 2020 Abstract: In March 2020, the World Health Organization declared the severe acute respiratory syndrome corona virus 2 (SARS-CoV2) infection to be a pandemic disease. SARS-CoV2 was first identified in China and, despite the restrictive measures adopted, the epidemic has spread globally, becoming a pandemic in a very short time. Though there is growing knowledge of the SARS-CoV2 infection and its clinical manifestations, an effective cure to limit its acute symptoms and its severe complications has not yet been found. Given the worldwide health and economic emergency issues accompanying this pandemic, there is an absolute urgency to identify effective treatments and reduce the post infection outcomes. In this context, phosphodiesterases (PDEs), evolutionarily conserved cyclic nucleotide (cAMP/cGMP) hydrolyzing enzymes, could emerge as new potential targets.
    [Show full text]
  • Various Subtypes of Phosphodiesterase Inhibitors Differentially Regulate Pulmonary Vein and Sinoatrial Node Electrical Activities
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 19: 2773-2782, 2020 Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities YUNG‑KUO LIN1,2*, CHEN‑CHUAN CHENG3*, JEN‑HUNG HUANG1,2, YI-ANN CHEN4, YEN-YU LU5, YAO‑CHANG CHEN6, SHIH‑ANN CHEN7 and YI-JEN CHEN1,8 1Department of Internal Medicine, Division of Cardiovascular Medicine, Wan Fang Hospital; 2Department of Internal Medicine, Division of Cardiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11696; 3Division of Cardiology, Chi‑Mei Medical Center, Tainan 71004; 4Division of Nephrology; 5Division of Cardiology, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei 22174; 6Department of Biomedical Engineering, National Defense Medical Center, Taipei 11490; 7Heart Rhythm Center and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217; 8Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11696, Taiwan, R.O.C. Received May 16, 2019; Accepted January 9, 2020 DOI: 10.3892/etm.2020.8495 Abstract. Phosphodiesterase (PDE)3-5 are expressed in 20.7±4.6%, respectively. In addition, milrinone (1 and 10 µM) cardiac tissue and play critical roles in the pathogenesis of induced the occurrence of triggered activity (0/8 vs. 5/8; heart failure and atrial fibrillation. PDE inhibitors are widely P<0.005) in PVs. Rolipram increased PV spontaneous activity used in the clinic, but their effects on the electrical activity by 7.5±1.3‑9.5±4.0%, although this was not significant, and did of the heart are not well understood. The aim of the present not alter SAN spontaneous activity.
    [Show full text]
  • Metabolic Enzyme/Protease
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
    [Show full text]
  • Structural Basis for the Activity of Drugs That Inhibit Phosphodiesterases
    Structure, Vol. 12, 2233–2247, December, 2004, ©2004 Elsevier Ltd. All rights reserved. DOI 10.1016/j.str.2004.10.004 Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases Graeme L. Card,1 Bruce P. England,1 a myriad of physiological processes, such as immune Yoshihisa Suzuki,1 Daniel Fong,1 Ben Powell,1 responses, cardiac and smooth muscle contraction, vi- Byunghun Lee,1 Catherine Luu,1 sual response, glycogenolysis, platelet aggregation, ion Maryam Tabrizizad,1 Sam Gillette,1 channel conductance, apoptosis, and growth control Prabha N. Ibrahim,1 Dean R. Artis,1 Gideon Bollag,1 (Francis et al., 2001). Cellular levels of cAMP and cGMP Michael V. Milburn,1 Sung-Hou Kim,2 are regulated by the relative activities of adenylyl and Joseph Schlessinger,3 and Kam Y.J. Zhang1,* guanylyl cyclases, which synthesize these cyclic nucleo- 1Plexxikon, Inc. tides, and by PDEs, which hydrolyze them into 5Ј-nucle- 91 Bolivar Drive otide monophosphates. By blocking phosphodiester hy- Berkeley, California 94710 drolysis, PDE inhibition results in higher levels of cyclic 2 Department of Chemistry nucleotides. Therefore, PDE inhibitors may have consid- University of California, Berkeley erable therapeutic utility as anti-inflammatory agents, Berkeley, California 94720 antiasthmatics, vasodilators, smooth muscle relaxants, 3 Department of Pharmacology cardiotonic agents, antidepressants, antithrombotics, Yale University School of Medicine and agents for improving memory and other cognitive 333 Cedar Street functions (Corbin and Francis, 2002; Rotella, 2002; Sou- New Haven, Connecticut 06520 ness et al., 2000). Of the 11 classes of human cyclic nucleotide phos- phodiesterases, the PDE4 family of enzymes is selective Summary for cAMP, while the PDE5 enzyme is selective for cGMP (Beavo and Brunton, 2002; Conti, 2000; Mehats et al., Phosphodiesterases (PDEs) comprise a large family 2002).
    [Show full text]